MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Predicts Growth for the Therapeutic Monoclonal Antibodies Market in Europe - Exploring the use of biologics to control rising disease incidence across the European therapeutics market - Pharma.frost.com
Frost & Sullivan Predicts Growth for the Therapeutic Monoclonal Antibodies Market in Europe

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/10/09 - Exploring the use of biologics to control rising disease incidence across the European therapeutics market - Pharma.frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Efficient resource to therapy of complex disorders with lesser side-effects has accelerated growth of monoclonal antibodies based therapeutics against conventional chemical drugs.

However, high developmental costs constitute a major barrier for mid-segment market entrants. Growing market opportunities generated by innovative treatment methods and existing product success rate will boost market growth.

New analysis from Frost & Sullivan, Analysis of the Therapeutic Monoclonal Antibodies Market in Europe, (pharma.frost.com), finds that the market earned revenues of $19.01 billion in 2011 and estimates this to reach $42.37 billion in 2018, at a compound annual growth rate (CAGR) of 12.1% from 2011-2018.

Monoclonal antibodies (mAbs) are mono-specific high molecular weight complex proteins that are capable of post translational modifications, such as glycosylation. They are commonly used biologics for therapeutics and therefore are the fastest growing segment within the biotechnology market.

mAbs are predominantly used in the treatment of cancer and autoimmune and inflammatory disorders. Other therapy areas using mAbs include cardiovascular and infectious diseases, as well as organ transplants.

"Technological development within the biotech and genomic markets triggered the use of mAbs for therapeutics," notes Frost & Sullivan Research Analyst Deepika Pramod Chopda. "With the rise in disease incidence rate and deterioration in human health conditions, the need for innovative and effective cure has been in great demand."

High developmental costs act however as a major barrier for market entrants due to the complex production process, expensive biological and chemical materials and clinical trials, as well as required safety, efficacy and quality tests.

The average production cost of developing monoclonal antibodies ranges from $650-$750 million and takes about 8 to 9 years. This factor particularly hinders the entrance of small biotech companies and favours big pharma participants, because of their financial strength and capabilities.

On the other hand, the rise in other specialty pharmaceuticals with biotech invasion is expected to expand therapeutics at niche levels, thereby creating opportunities for bigger and better biologics business.

"Alliances between big pharma and small biotech firms for developing biologics is a key trend observed in this market," adds Deepika. "High developmental costs due to expensive research and testing activities trigger the overall expenditure of mAbs. Alliances with financially adept companies will help small biotech firms to develop new technologies, thus encouraging product development within this market."

If you are interested in more information on this study, please send an email with your contact details to Anna Zanchi, Corporate Communications, at anna.zanchi[.]frost.com.

Analysis of the Therapeutic Monoclonal Antibodies Market in Europe is part of the Pharmaceutical and Biotechnology Growth Partnership Service programme, which also includes research in the following markets: European Biosimilars Market, Global Generics Market and European Autoimmune Diseases Therapeutics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Predicts Growth for the Therapeutic Monoclonal Antibodies Market in Europe

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Anna Zanchi 
+39 02 46514819 anna.zanchi[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Data Presented During ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs
Global Pharmaceutical Contract Manufacturing Organization Market to Reach 2.14 Billion by 2024 Finds Frost & Sullivan
Ipsen’s Palovarotene Clinical Program in Fibrodysplasia Ossificans Progressiva Reaches Prespecified Interim Analysis Futility Criteria
Global Bio-based Chemicals Market is Expected to Grow At A CAGR of 16.67% by 2027 According to Inkwood Research
Global Diabetes Drugs Market Forecast 2019-2027 Reports Inkwood Research
Dysport® Now Approved in the UK for Symptomatic Treatment of Upper Limb Spasticity in Children with Cerebral Palsy
Human Microbiome Market to Reach .08 Billion by 2023, Powered by the High Growth in Over-the-Counter Probiotics Finds Frost & Sullivan
BASF Launches Hepacor in Switzerland for the Dietary Management of Non-Alcoholic Fatty Liver Disease
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy
Ipsen Presents New Analyses Utilizing Modern Data Mining Approaches At ISPOR Europe 2019
Global Opioids Drugs Market is Projected to Grow At a CAGR of 2.52% by 2027 Reports Inkwood Research
Global Bio-Based Chemicals Market Projected to Grow At a CAGR of 16.67% by 2027 Finds Inkwood Research
The Global Animal Nutrition Market Projected to Grow At a CAGR of 5.94% by 2027 Finds Inkwood Research
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-small Cell Lung Cancer
BTG to Invest in Chinese Medical Isotope Diagnosis and Treatment Company Chengdu New Radiomedicine Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  BizJobs.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)